SAN DIEGO , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a business update announcing the U.S. launch of FDA -approved SYMJEPI ™ (epinephrine) 0.3mg Injection is planned for early Q1 2019. Adamis has continued to work closely with Sandoz Inc.
SAN DIEGO , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a business update announcing the U.S. launch of FDA -approved SYMJEPI ™ (epinephrine) 0.3mg Injection is planned for early Q1 2019. Adamis has continued to work closely with Sandoz Inc.
SAN DIEGO , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2018 and a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , stated,
SAN DIEGO , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2018 and a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , stated,
SAN DIEGO , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved Adamis’ lower dose version (0.15mg) of Symjepi ™ for the emergency treatment of allergic reactions (Type I)
SAN DIEGO , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved Adamis’ lower dose version (0.15mg) of Symjepi ™ for the emergency treatment of allergic reactions (Type I)
SAN DIEGO , Aug. 27, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , said, “We have been receiving a considerable amount of inquiries from investors,
SAN DIEGO , Aug. 27, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , said, “We have been receiving a considerable amount of inquiries from investors,
SAN DIEGO , Aug. 10, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2018 and a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , stated,
SAN DIEGO , Aug. 10, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2018 and a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , stated,
SAN DIEGO , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today the closing of
SAN DIEGO , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today the closing of
SAN DIEGO , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today the pricing of
SAN DIEGO , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today the pricing of
SAN DIEGO , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today that it
SAN DIEGO , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today that it
SAN DIEGO , July 23, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today that it has been conducting pre-IND development work for a fast-dissolving sublingual tablet containing tadalafil. Adamis intends to submit an investigational new drug (IND)
SAN DIEGO , July 23, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today that it has been conducting pre-IND development work for a fast-dissolving sublingual tablet containing tadalafil. Adamis intends to submit an investigational new drug (IND)
SAN DIEGO , July 01, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today that it has entered into an exclusive distribution and commercialization agreement with Sandoz Inc. (“Sandoz”), a division of the Novartis Group , to commercialize Adamis’
SAN DIEGO , July 01, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today that it has entered into an exclusive distribution and commercialization agreement with Sandoz Inc. (“Sandoz”), a division of the Novartis Group , to commercialize Adamis’
SAN DIEGO , May 10, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced financial results and a business update for the first quarter ended March 31, 2018 . Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , said, “We have
SAN DIEGO , May 10, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced financial results and a business update for the first quarter ended March 31, 2018 . Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , said, “We have
SAN DIEGO , March 15, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today provided investors with an update concerning certain accomplishments for 2017 and accomplishments and goals for 2018. 2017 Highlights As reflected in the company’s annual report on Form 10-K for
SAN DIEGO , March 15, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today provided investors with an update concerning certain accomplishments for 2017 and accomplishments and goals for 2018. 2017 Highlights As reflected in the company’s annual report on Form 10-K for
SAN DIEGO , March 08, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today announced that a study titled “Human Factors Study in Untrained Adolescents Comparing Its Epinephrine Prefilled Syringe (Symjepi™) with EpiPen® Auto-Injector” was recently published in
SAN DIEGO , March 08, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today announced that a study titled “Human Factors Study in Untrained Adolescents Comparing Its Epinephrine Prefilled Syringe (Symjepi™) with EpiPen® Auto-Injector” was recently published in
SAN DIEGO , March 06, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today provided an update on data from its presentation entitled “Human Factors Study of A Newly Approved Epinephrine Prefilled Syringe (Symjepi) for the Emergency Treatment of Allergic
SAN DIEGO , March 06, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today provided an update on data from its presentation entitled “Human Factors Study of A Newly Approved Epinephrine Prefilled Syringe (Symjepi) for the Emergency Treatment of Allergic
SAN DIEGO , Feb. 23, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today provided an update on the progress of exploring commercialization options relating to the commercial launch of its Symjepi TM (epinephrine) Injection 0.3mg product, for the emergency treatment of
SAN DIEGO , Feb. 23, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today provided an update on the progress of exploring commercialization options relating to the commercial launch of its Symjepi TM (epinephrine) Injection 0.3mg product, for the emergency treatment of
SAN DIEGO , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review the Company’s supplemental New Drug Application (“sNDA”) for its low dose Symjepi TM
SAN DIEGO , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review the Company’s supplemental New Drug Application (“sNDA”) for its low dose Symjepi TM
SAN DIEGO , Dec. 06, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today announced that its subsidiary, US Compounding, has developed a unique compound to manage ulcers in horses. Ulcers are common in the majority of horses that are subject to stress.
SAN DIEGO , Dec. 06, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today announced that its subsidiary, US Compounding, has developed a unique compound to manage ulcers in horses. Ulcers are common in the majority of horses that are subject to stress.
SAN DIEGO , Dec. 04, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration ( FDA ) to begin testing the drug compound naloxone in human patients.
SAN DIEGO , Dec. 04, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration ( FDA ) to begin testing the drug compound naloxone in human patients.
SAN DIEGO, Dec. 01, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation ( ADMP ) (“Adamis”) announced today the acceptance of a presentation entitled “Human Factors Study of A Newly Approved Epinephrine Prefilled Syringe (Symjepi) for the Emergency Treatment of Allergic Reactions (Type I)
SAN DIEGO, Dec. 01, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation ( ADMP ) (“Adamis”) announced today the acceptance of a presentation entitled “Human Factors Study of A Newly Approved Epinephrine Prefilled Syringe (Symjepi) for the Emergency Treatment of Allergic Reactions (Type I)
SAN DIEGO , Nov. 29, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced the submission of a prior approval supplement to the U.S. Food and Drug Administration (“FDA”) for a pediatric version (0.15mg) of Symjepi™.
SAN DIEGO , Nov. 29, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced the submission of a prior approval supplement to the U.S. Food and Drug Administration (“FDA”) for a pediatric version (0.15mg) of Symjepi™.
SAN DIEGO , June 15, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved Adamis’ EPINEPHRINE INJECTION, USP, 1:1000 (0.3 mg Pre-filled single dose syringe) (“PFS”) for the emergency
SAN DIEGO , June 15, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved Adamis’ EPINEPHRINE INJECTION, USP, 1:1000 (0.3 mg Pre-filled single dose syringe) (“PFS”) for the emergency
SAN DIEGO , April 26, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy, announced today the closing of its previously
SAN DIEGO , April 26, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy, announced today the closing of its previously
SAN DIEGO , April 21, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy, announced today the pricing of its previously
SAN DIEGO , April 21, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy, announced today the pricing of its previously
SAN DIEGO , April 20, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy, announced today that it intends to offer to sell
SAN DIEGO , April 20, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy, announced today that it intends to offer to sell
SAN DIEGO , Jan. 19, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review the Company’s New Drug Application (“NDA”) for its Epinephrine Pre-filled Syringe (“PFS”)
SAN DIEGO , Jan. 19, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review the Company’s New Drug Application (“NDA”) for its Epinephrine Pre-filled Syringe (“PFS”)
